The lawsuit relates to high frequency paresthesia-free spinal cord stimulation therapy.
Nevro sought preliminary and permanent injunctive relief against further infringement as well as damages and attorney’s fees, according to a Dec. 14 news release. The company received none of the requested relief.
As Boston Scientific does not have any plans to launch a high frequency spinal cord stimulation system in the U.S, both parties agreed to dismiss the case.
The decision is subject to approval of the court.
The dismissal will not affect Boston Scientific’s patent infringement and trade secret misappropriation cases against Nevro in Delaware. The first trial is set for October 2021.
More articles on devices:
How CMS’ changes will affect spine surgeons in 2021 — Prior authorization, fee cuts & more
Former orthopedic practice owner gets 5 years in prison for illegally prescribing opioids
Surgeons’ brand exceeds patient outcomes — How you should build your practice’s brand
